We are proud to announce the successful first-in-human implantation of our innovative Zenith left atrial appendage occlusion (LAAO) device. The procedure, performed at Auckland City Hospital, is a crucial step in the clinical validation of our novel technology. “I am very encouraged by how the Zenith device performed in this important first case. The patient recovered exceptionally well” said Dr Matt O’Connor the implanting cardiologist. “The independent anchors of the Zenith device provide a distinct advantage by allowing easy repositioning and placement optimization of the implant without risking injury to the heart. This in combination with the intra-procedural leak analysis, represents a significant advance in the LAAO technology.”
Approach
Mission, Vision & Values
OUR MISSION
To be leaders in curing chronic cardiac disease & restoring patients to people
OUR VISION
To deliver pioneering, life changing solutions for patients with chronic cardiac disease
OUR VALUES
INTEGRITY
We prioritize patient care and product quality
ATTITUDE
We believe that anything is possible
TEAM
We believe in great people, great culture, having fun & celebrating our accomplishments
GROWTH
We prioritize learning through open communication and collaboration to challenge assumptions, think deeply, and continuously improve
Traction
International Awards & Recognition
Selected to present our disruptive technology at two separate Euro PCR conferences
Winner of pitch competition
SME instrument Ranked 1st of 1280 companies
FTI instrument Ranked 1st of 138 companies
1st Irish company accepted to the prestigious Texas Medical Centre Accelerator
Winner of the prestigious ICI Global Innovation Award in Tel Aviv
The Medtech industry’s Accelerator and Venture Competition for transformative innovations
Awarded non-dilutive grant assistance through the DTI Fund of the Irish Government
ATU Innovation Hubs
Dublin Road
Galway
H91 DCH9
Ireland
AuriGen Medical has received grants from the following Governmental agencies:
